Aigen Investment Management LP Purchases Shares of 4,663 Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Aigen Investment Management LP bought a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 4,663 shares of the company's stock, valued at approximately $395,000.

A number of other institutional investors have also bought and sold shares of the business. Assetmark Inc. bought a new position in shares of Axsome Therapeutics in the fourth quarter worth about $52,000. R Squared Ltd purchased a new position in Axsome Therapeutics in the 4th quarter worth approximately $64,000. KBC Group NV boosted its stake in Axsome Therapeutics by 40.5% in the 4th quarter. KBC Group NV now owns 1,336 shares of the company's stock worth $113,000 after purchasing an additional 385 shares during the period. Moors & Cabot Inc. purchased a new stake in Axsome Therapeutics during the 3rd quarter valued at approximately $200,000. Finally, Whalen Wealth Management Inc. purchased a new stake in Axsome Therapeutics during the 3rd quarter valued at approximately $236,000. Hedge funds and other institutional investors own 81.49% of the company's stock.

Insider Activity at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 3,000 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the transaction, the chief financial officer now owns 42,187 shares of the company's stock, valued at $5,529,450.09. This represents a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 22.40% of the stock is currently owned by company insiders.

Remove Ads

Wall Street Analysts Forecast Growth

AXSM has been the subject of several research analyst reports. Truist Financial raised their target price on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. HC Wainwright restated a "buy" rating and set a $200.00 price objective on shares of Axsome Therapeutics in a research report on Thursday, March 6th. Needham & Company LLC reiterated a "buy" rating and issued a $153.00 target price on shares of Axsome Therapeutics in a research report on Monday, March 3rd. StockNews.com upgraded Axsome Therapeutics from a "sell" rating to a "hold" rating in a report on Wednesday, November 20th. Finally, Deutsche Bank Aktiengesellschaft began coverage on Axsome Therapeutics in a research note on Tuesday, February 11th. They issued a "buy" rating and a $176.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. Based on data from MarketBeat, Axsome Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $167.36.

Axsome Therapeutics Trading Up 0.6 %

Shares of AXSM traded up $0.72 during mid-day trading on Tuesday, reaching $119.50. 824,699 shares of the company's stock traded hands, compared to its average volume of 656,929. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04. The stock's 50-day moving average is $109.46 and its two-hundred day moving average is $98.05. Axsome Therapeutics, Inc. has a 12 month low of $64.11 and a 12 month high of $139.13. The stock has a market cap of $5.83 billion, a P/E ratio of -19.95 and a beta of 1.00.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, beating the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The company had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million. Research analysts forecast that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.